Chronic Lymphocytic Leukemia | Specialty

Dr. Barr on Exploring U2 Plus Venetoclax in Relapsed/Refractory CLL

January 4th 2021

Paul M. Barr, MD, discusses exploring umbralisib plus ublituximab plus venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Al-Sawaf on the Next Steps of the CLL14 Trial in CLL

January 4th 2021

Othman Al-Sawaf, MD, a physician with the University Hospital of Cologne in Germany, discusses the next steps of the CLL14 trial in chronic lymphocytic leukemia.

Dr. Rogers on Assessing MRD After Obinutuzumab/Ibrutinib/Venetoclax in CLL

January 4th 2021

Kerry Rogers, MD, discusses the minimal residual disease assessment component of a phase 2 trial evaluating obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia.

Dr. Barr on the Need to Develop Novel Therapies in CLL

December 23rd 2020

Paul M. Barr, MD, discusses the need to develop novel therapies in chronic lymphocytic leukemia.

Dr. Allan on the Safety Profile of Ibrutinib in High-Risk CLL

December 23rd 2020

John N. Allan, MD, discusses the safety profile of ibrutinib in high-risk chronic lymphocytic leukemia.

Rapid Readouts: Five-Year Analysis of MURANO Study

December 23rd 2020

Dr. Al-Sawaf on the Limitations of Continuous Therapy Administration in CLL

December 22nd 2020

Othman Al-Sawaf, MD, discusses the limitations of continuous therapy administration in chronic lymphocytic leukemia.

Modern Paradigm Comprises New Agents and Optimal Patient Selection in CLL

December 18th 2020

Javier L. Munoz, MD, discusses the nuances of choosing treatment options for patients with CLL in the frontline and relapsed/refractory settings, as well as novel therapeutic strategies on the horizon.

FDA Approves Rituximab Biosimilar for NHL, CLL, GPA, and MPA

December 17th 2020

December 17, 2020 - The FDA has approved rituximab-arrx, a biosimilar to rituximab, for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.

Venetoclax/Rituximab Combo Demonstrates Sustained Benefit for Retreated Patients with CLL

December 8th 2020

December 8, 2020 - The combination of venetoclax and rituximab to retreat patients with relapsed/refractory chronic lymphocytic leukemia demonstrated a sustained time to next treatment benefit according to 5-year follow-up data of the MURANO study in a poster presentation at the 2020 ASH Meeting.

Umbralisib/Ublituximab Plus Venetoclax Induces High Objective Response Rate in Relapsed/Refractory CLL

December 8th 2020

December 8, 2020 - The combination of umbralisib plus ublituximab plus venetoclax demonstrated encouraging efficacy as treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including those who are refractory to prior therapy with a Bruton tyrosine kinase inhibitor.

LOXO-305 Elicits Impressive Responses in Previously Treated CLL/SLL

December 8th 2020

LOXO-305, an investigational, highly selective, non-covalent BTK inhibitor, demonstrated an investigator-assessed 63% objective response rate in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Liso-Cel Shows Durable Responses in Patients with Relapsed/Refractory CLL/SLL

December 8th 2020

December 7, 2020 - In high-risk patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, lisocabtagene maraleucel treatment resulted in a high rate of undetectable minimal residual disease with rapid and durable responses

Ublituximab/Umbralisib Outperforms Chemoimmunotherapy in Patients with CLL

December 7th 2020

December 7, 2020 — The combination of ublituximab and umbralisib, 2 novel compounds targeting CD20 and PI3Kδ, respectively, has shown synergistic activity in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy irrespective of prior treatment.

Dr. Wierda on the Results of the CAPTIVATE Trial in CLL and SLL

December 5th 2020

William G. Wierda, MD, PhD, discusses results from the CAPTIVATE trial in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Survival Benefit of Venetoclax and Rituximab in Relapsed/Refractory CLL Persists Out to Five Years

December 5th 2020

December 5, 2020 - Patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax and rituximab had a sustained progression-free survival and overall survival benefit at five years compared with those treated with bendamustine and rituximab.

Continued Ibrutinib, Post Fixed-Duration of Ibrutinib/Venetoclax, Elicits Similar 1-Year DFS Vs Placebo in CLL/SLL

December 5th 2020

December 5, 2020 - Patients with previously untreated chronic lymphocytic leukemia /small lymphocytic lymphoma who received a placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease.

Dr. Seymour on Investigational BTK Inhibitors in CLL

December 4th 2020

Erlene Seymour, MD, discusses investigational BTK inhibitors in chronic lymphocytic leukemia.

Evolving Data for CLL Set Stage for Frontline Therapy

December 4th 2020

In a recent OncLive Peer Exchange®, a panel of hematologic experts discusses the paradigm shift in frontline therapy options for patients with CLL.

Treatment Considerations in Newly Diagnosed CLL

December 4th 2020

Drs Stilgenbauer and Ghia provide insight on initial treatment considerations for patients with newly diagnosed chronic lymphocytic leukemia.